FDA Warns Against Concurrent Use Of Triptans With SSRIs/SNRIs

The agency has received reports of serotonin syndrome caused by use of the migraine therapy class with antidepressants, according to a public health advisory.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet